pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·1h ago·1 min read
save

Roche enters the SERD market with FDA approval in late-stage breast cancer

Roche’s big-hope breast cancer pill giredestrant was in an odd situation in that it was awaiting two different FDA approval decisions. Also oddly, the second one came first. The drug was

Nov 17, 2026·read at Endpoints ↗

November 17, 2026 07:00 AM EST PharmaFDA+ Roche en­ters the SERD mar­ket with FDA ap­proval in late-stage breast can­cer Elizabeth Cairns Senior biopharma journalist Roche’s big-hope breast can­cer pill giredestrant was in an odd sit­u­a­tion in that it was await­ing two dif­fer­ent FDA ap­proval de­ci­sions. Al­so odd­ly, the sec­ond … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
84 words · retrieved 5m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1h agoMarrow raises $173M for siRNA drug competing with CRISPR therapy for sickle cellEndpoints
  • 14h ago#CTAD26: AriBio’s repurposing of ED drug for Alzheimer’s yields tepid resultsEndpoints
  • 16h agoLilly strikes up to $5.9B cancer deal with Stipple BioEndpoints
  • 17h agoAstraZeneca, Alexion's myasthenia gravis treatment enters crowded marketEndpoints
  • 18h agoHelus Pharma notches successful Phase 3 depression readoutEndpoints